Prodrugs

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R is selected from -(1-6C)alkyl, -(1-4C)alkylene-X—R1, and -(1-4C)alkylene-R2.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R is selected from -(1-4C)alkyl, -(1-2C)alkylene-X—R1, and -(1-2C)alkylene-R2.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R is selected from -methyl, -ethyl, -isopropyl, -tertbutyl, -methylene-X—R1, -ethylene-X—R1 and -methylene-R2.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein X is selected from —O—, —C(O)—, —C(O)O—, —O—C(O)—, —O—C(O)—O—, —CH(ORA)—, —N(RA)—, —N(RA)—C(O)—, —N(RA)—C(O)O—, —C(O)—N(RA)—, —N(RA)C(O)N(RA)—, —S—, —SO—, —SO2—, —S(O)2N(RA)—, or —N(RA)SO2— wherein each RA is independently selected from hydrogen or (1-6C)alkyl.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein X is selected from —O—, —C(O)—, —C(O)O—, —O—C(O)—, —O—C(O)—O—, —N(RA)—, —N(RA)—C(O)— or —C(O)—N(RA)—, wherein RA is selected from hydrogen or (1-3C)alkyl.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein X is selected from —C(O)—, —C(O)O—, —O—C(O)—, —O—C(O)—O—, —N(H)— or —N(Me)—.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein X is selected from —O—C(O)—, —O—C(O)—O— or —N(Me)—.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R1 is selected from -hydrogen, -(1-6C)alkyl, -(2-6C)alkenyl, -(2-6C)alkynyl, -aryl, -(3-6C)cycloalkyl, -(3-6C)cycloalkenyl, -heteroaryl or -heterocyclyl.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R1 is selected from -hydrogen, -(1-5C)alkyl, -aryl, -(3-6C)cycloalkyl, -(3-6C)cycloalkenyl, -heteroaryl or -heterocyclyl.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R1 is selected from -hydrogen, -methyl, -ethyl, -propyl (e.g. n-propyl and iso-propyl), -butyl (e.g. n-butyl, iso-butyl, sec-butyl and tert-butyl), -phenyl, cyclopentane, cyclohexane, -5- or -6-membered heteroaryl or -5- or -6-membered heterocyclyl, wherein said heteroaryl or heterocyclyl comprises 1 or 2 heteroatoms selected from N, O and S.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R1 is selected from -hydrogen, -methyl, -ethyl, -propyl (e.g. n-propyl and iso-propyl), -butyl (e.g. n-butyl, iso-butyl, sec-butyl and tert-butyl) or -6-membered heterocyclyl, wherein said heterocyclyl comprises 1 or 2 heteroatoms selected from N and O.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is selected from -aryl, -(3-6C)cycloalkyl, -(3-6C)cycloalkenyl, -heteroaryl or -heterocyclyl, wherein R2 is optionally substituted by one or more substituents independently selected from -halo, -hydroxy, -cyano, -amino, -(1-4C)alkyl, -(1-4C)alkoxy, -oxo, —C(O)—RB, —C(O)O—RB or —C(O)—N(RB)2, wherein each RB is independently selected from hydrogen or (1-6C)alkyl.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is selected from -phenyl, -(4-6C)cycloalkyl, -(4-6C)cycloalkenyl, -5-, or -6-membered heteroaryl or -5-, or -6-membered heterocyclyl, wherein said heteroaryl or heterocyclyl comprises 1, 2 or 3 heteroatoms selected from N, O and S, wherein R2 is optionally substituted by one or more substituents independently selected from -halo, -hydroxy, -cyano, -amino, -(1-3C)alkyl, -(1-3C)alkoxy, -oxo, —C(O)—RB, —C(O)O—RB or —C(O)—N(RB)2, wherein each RB is independently selected from hydrogen or (1-3C)alkyl.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is selected from −5-, or -6-membered heteroaryl or -5-, or -6-membered heterocyclyl, wherein said heteroaryl or heterocyclyl comprises 1 or 2 heteroatoms selected from N and O, wherein R2 is optionally substituted by one, two or three substituents independently selected from -halo, -hydroxy, -cyano, -amino, -(1-3C)alkyl, -(1-3C)alkoxy, -oxo, —C(O)—H, —C(O)O—H or —C(O)—N(H)2, —C(O)—Me, —C(O)O-Me or —C(O)—N(Me)2.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is a dioxole (e.g. 1,2-dioxole or 1,3-dioxole), wherein R2 is optionally substituted by two substituents independently selected from -halo, -hydroxy, -cyano, -amino, -(1-3C)alkyl, -(1-3C)alkoxy, -oxo, —C(O)—H, —C(O)O—H or —C(O)—N(H)2, —C(O)—Me, —C(O)O-Me or —C(O)—N(Me)2.

The compound according to any one of the preceding claims, or a pharmaceutically acceptable salt, hydrate or solvate thereof, wherein R2 is 1,3-dioxole, wherein R2 is substituted by one methyl group and one oxo group.